0001415889-24-004003.txt : 20240215 0001415889-24-004003.hdr.sgml : 20240215 20240215204002 ACCESSION NUMBER: 0001415889-24-004003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Regnante Keith CENTRAL INDEX KEY: 0001682068 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 24645550 MAIL ADDRESS: STREET 1: 733 CONCORD AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02138 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811173868 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-314-6297 MAIL ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form4-02162024_010256.xml X0508 4 2024-02-13 0001664710 Keros Therapeutics, Inc. KROS 0001682068 Regnante Keith C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 false true false false CHIEF FINANCIAL OFFICER 0 Employee Stock Option (right to buy) 56.18 2024-02-13 4 A 0 40000 0 A 2034-02-12 Common Stock 40000 40000 D 25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. /s/ Keith Regnante 2024-02-15